Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...
Eurocine Vaccines AB has reported findings from preclinical studies evaluating its mRNA and protein technology platforms for its therapeutic herpes simplex virus type 2 (HSV-2) vaccine candidates.
HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...
WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced ...
Half of the individuals with genital herpes simplex virus (HSV) infection experience several recurrence episodes per year, especially if the causative agent is HSV type 2 (HSV-2). Standard-of-care ...
Assembly Biosciences (NASDAQ:ASMB) reported promising results from an early stage study of its experimental candidate, ABI-5366, a new treatment aimed against herpes simplex virus. This study involved ...
NEW YORK (Reuters Health) - Therapy with valacyclovir (Valtrex, GlaxoSmithKline), started within three months of infection with either herpes simplex virus type 1 (HSV-1) or HSV type 2 (HSV-2), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results